News & Events

Life Science Leader, October 2009
Written by: Dan Schell

New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events.
Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug
development process


NEW YORK--(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation. The site will be the first to focus on patient privacy rights to connect patients, physicians and researchers with tailored information, tools and technology that will lead to more informed decisions about patient care, including clinical trial participation industry-wide.


CEO & Chairman Jim Walker of Octagon Research Solutions, Inc., a pioneer and leading provider of breakthrough software and services to the life sciences industry, announced today that Brian Shilling, senior manager, Clinical Programming, Octagon Research Solutions, Inc. received an Award of Excellence within the Technical Publications Competition from the Society of Technical Communication (STC), Carolina Chapter. This award honored his book entitled, Validating Clinical Trial Data Reporting with SAS®, which was co-authored with Carol I. Matthews and published in conjunction with SAS Press, a unit of business analytics software leader SAS Institute Inc.


DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed an agreement with Eli Lilly and Company (NYSE: LLY) to manage the company’s clinical data management business outside the United States. The agreement, which spans more than three dozen countries, excluding the United States and Japan, will help to transform Lilly’s research and development organisation as they seek to drive productivity, gain speed to market and lower drug development costs